Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Neuroendocrine tumours in 2016

Defining rules for increasingly personalized treatments

In 2016, results of an extensive trial broadened the range of malignancies that can be treated with everolimus to include neuroendocrine tumours (NETs) of the lung and gastrointestinal tract. Furthermore, studies aimed at identifying biomarkers with increased specificity, and at better defining high-grade NETs have enabled substantial progress towards delivering effective targeted treatments to patients with NETs.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 387, 968–977 (2016).

    Article  CAS  PubMed  Google Scholar 

  2. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO Classification of Tumours of the Digestive System Vol. 3 (IARC, 2010).

    Google Scholar 

  4. Tang, L. H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22, 1011–1017 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 40, 1192–1202 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Strosberg, J. et al. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate: efficacy, safety, QOL results and subgroups analysis [abstract]. Ann. Oncol. 27 (Suppl. 6), vi136–vi148 (2016).

    Google Scholar 

  7. Bodei, L. et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 43, 839–851 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Khan, M. S. et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin. Cancer Res. 22, 79–85 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank L. Zampaglione for her assistance with manuscript editing.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Falconi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falconi, M., Partelli, S. Defining rules for increasingly personalized treatments. Nat Rev Clin Oncol 14, 80–82 (2017). https://doi.org/10.1038/nrclinonc.2016.197

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.197

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research